Fermer le menu


Member of Lyonbiopole


Metabolys has a drug discovery activity in the NASH (Non Alcoholic SteatoHepatitis)/diabetes field. For this, Metabolys has hired the former head of the medicinal chemistry department of Merck Santé France, a subsidiary of Merck Serono, where he directed 30 chemists. He conceived the chemical synthesis of potential antidiabetic candidates whose synthesis was out-sourced. Out of 195 molecules tested, Metabolys has discovered and protected 8 antidiabetic candidates with 3 international patents. The most original one, which is very efficient for treating type 2 diabetes and NASH in animal models and is also protected by an international patent for treating NASH, is in the late phase of preclinical development thanks to a metabolic platform developed at Metabolys and a multi-disciplinary team of experts in metabolic diseases.



Strategic application domain: Human Medicine

Application market: Gastro-enterology, Metabolic Disorders - Endocrinology

Type of activity: Therapeutics, Pharma or Biotech

Created on nov. 20th, 2008 - 4 employees



181 avenue Jean Jaurès 69007 Lyon



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.